First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis
详细信息 查看全文
- 作者：Benoî ; t Rousseau ; MD ; MSca ; b ; c ; benoit.rousseau@aphp.fr" class="auth_mail" title="E-mail the corresponding author ; ben.rousseau@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Emmanuelle Kempf ; MD ; MSca ; Gaelle Desamericq ; PharmD ; PhDd ; Emilie Boissier ; MD ; MSca ; Marie Chaubet-Houdu ; MDa ; b ; Charlotte Joly ; MDa ; b ; Carolina Saldana ; MD ; MSca ; b ; Helene Boussion ; MDa ; b ; Cindy Neuzillet ; MD ; MSca ; b ; Isabelle Macquin-Mavier ; MD ; PhDa ; b ; Sté ; phane Oudard ; MD ; PhDe ; Laurent Salomon ; MD ; PhDb ; f ; Alexandre de la Taille ; MD ; PhDb ; f ; Christophe Tournigand ; MD ; PhDa ; b
- 关键词：Renal cell carcinoma ; Angiogenesis inhibitors ; Meta-analysis
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：107
- 期：Complete
- 页码：44-53
- 全文大小：906 K
文摘
- •
Five antiangiogenic drugs are recommended as initial treatment of metastatic renal cell carcinoma patients.
- •
Sunitinib, pazopanib, axitinib and bevacizumab + interferon alpha-2a yield a similar survival benefit but have different safety profiles.
- •
These results may provide guidance to optimize treatment choices.